NBTX vs NVCR vs ARAY vs SENS vs ONCO

For growth investors, Senseonics Holdings, Inc.

(SENS) is the stronger pick with 56. 9% revenue growth year-over-year, versus -132. 1% for Nanobiotix S. A. (NBTX). Analysts rate Nanobiotix S. A. (NBTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nanobiotix S.

A. (NBTX) delivered a total return of +182. 9%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: NBTX returned +150. 9% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Onconetix, Inc.

(ONCO) is the lower-risk stock at 1. 41β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately 71% more volatile than ONCO relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Senseonics Holdings, Inc.

(SENS) is pulling ahead at 56. 9% versus -132. 1% for Nanobiotix S. A. (NBTX). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to -33. 3% for Nanobiotix S. A.. Over a 3-year CAGR, SENS leads at 29. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nanobiotix S.

A. (NBTX) is the more profitable company, earning 586. 9% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 586. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBTX leads at 589. 1% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — NBTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ONCO (30.

9% yield) pays a dividend. NBTX, NVCR, ARAY, SENS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Onconetix, Inc.

(ONCO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (30. 9% yield). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONCO: -100. 0%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NBTX is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock; SENS is a small-cap high-growth stock; ONCO is a small-cap income-oriented stock. ONCO pays a dividend while NBTX, NVCR, ARAY, SENS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.